Find your patients’ dosing
For Max SoloStar® and SoloStar®
Toujeo® T2DM Dosing Calculator
Determine a patient's starting dose based on body weight1*
Enter a patient's weight (lbs)—to calculate the recommended starting dose
T2DM, type 2 diabetes mellitus.
*Units of Toujeo are rounded down to the nearest whole unit and are calculated based on a recommended starting dose of 0.2 Units/kg. For dosing information in specific populations such as type 1 diabetes mellitus, please see the full Prescribing Information for Toujeo.
The dosage of other antidiabetic drugs may need to be adjusted when starting Toujeo to minimize the risk of hypoglycemia. View additional dosing information in the full Prescribing Information.
What to do when switching from Toujeo SoloStar to Toujeo Max SoloStar:
- Toujeo Max SoloStar is recommended for patients requiring at least 20 units per day
- Toujeo Max SoloStar delivers doses in 2 unit increments
- When changing between Toujeo SoloStar and Toujeo Max SoloStar, if the patient’s previous dose was an odd number, the next dose should be increased or decreased by 1 unit
What to know when prescribing Toujeo
(6 mL/1800 Units)
(12 mL/3600 Units)
(18 mL/5400 Units)
- NDC: 0024-5869-03
- 300 Units/mL formulation
- 1.5 mL and 450 Units per pen
- 3 pens (4.5 mL and 1350 Units total) per box
Determine how many boxes of Toujeo SoloStar a patient will need
1 box provides…
Up to 45 Units/day
(total supply dispensed: 4.5 mL)
2 boxes provide…
(total supply dispensed: 9 mL)
3 boxes provide…
(total supply dispensed: 13.5 mL)
Unopened pens should be stored in a refrigerator (between 36°F and 46°F) until expiration date; when opened, store at room temperature
The starting dose of Toujeo is based on prior treatment
Start based on weight
TIP: Use the dosing calculator for a suggested starting dose
Basal insulin switch?
A 1:1 conversion for once-daily basal insulins to start
Taking twice-daily NPH or insulin detemir?
80% of total daily dose
Titrate according to patients’ specific needs and history‡
Set titration goals based on patient needs2*
Individualized based on FPG goal
Adjust and titrate no more frequently than every 3-4 days to reduce the risk of hypoglycemia1
More or less stringent goals may be appropriate for individual patients.
- In clinical trials, patients started on, or changed to, Toujeo required a higher dose than patients controlled on Lantus®1
- Monitor glucose frequently in the first few weeks of therapy
- The maximum glucose-lowering effect of a dose of Toujeo may take 5 days to fully manifest, and the first Toujeo dose may be insufficient to cover metabolic needs in the first 24 hours of use
FPG, fasting plasma glucose.
‡ADA glycemic recommendations for fasting or pre-meal plasma glucose for non-pregnant adults with diabetes: 80-130 mg/dL.2
Ensure patients have a prescription for Toujeo as well as a second, separate prescription for pen needles.
Toujeo is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus.
Limitations of Use: Toujeo is not recommended for treating diabetic ketoacidosis.
Important Safety Information
Important Safety Information
Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.
Warnings and Precautions
Toujeo contains the same active ingredient, insulin glargine, as Lantus®. The concentration of insulin glargine in Toujeo is 300 units per mL.
Insulin pens and needles must never be shared between patients. Do NOT reuse needles.
Monitor blood glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision. Changes in insulin regimen, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia.
Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.
Unit for unit, patients started on, or changed to, Toujeo required a higher dose than patients controlled with Lantus. When changing from another basal insulin to Toujeo, patients experienced higher average fasting plasma glucose levels in the first few weeks of therapy until titrated to their individualized fasting plasma glucose targets. Higher doses were required in titrate-to-target studies to achieve glucose control similar to Lantus.
Hypoglycemia is the most common adverse reaction of insulin therapy, including Toujeo, and may be life-threatening.
Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection.
Do not dilute or mix Toujeo with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Toujeo via an insulin pump or intravenously because severe hypoglycemia can occur.
Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Toujeo, monitor and treat if indicated.
A reduction in the Toujeo dose may be required in patients with renal or hepatic impairment.
As with all insulins, Toujeo use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.
Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.
Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).
Adverse reactions commonly associated with Toujeo include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.
Important Safety Information for Toujeo SoloStar® and Toujeo Max SoloStar®
Toujeo SoloStar and Toujeo Max SoloStar are single-patient-use prefilled insulin pens. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose levels. It is especially important to perform a safety test when a patient is using a new pen for the first time.
Do not withdraw Toujeo from the SoloStar and Max SoloStar single-patient-use prefilled pens with a syringe.
All registered trademarks cited are property of their respective owners.
†Eligibility Restrictions and Offer Terms:
This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use the savings card. The Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend the program without notice.
- Pay as low as $0 up to $99 for a 30-day supply, depending on insurance coverage. Valid up to 10 packs per fill; Offer valid for one fill per 30-day supply.
References: 1. Toujeo® Prescribing Information. 2. American Diabetes Association. Diabetes Care. 2021;44(Suppl. 1):S1-S244.